MX359854B - Anticuerpos anti-cxcr3. - Google Patents
Anticuerpos anti-cxcr3.Info
- Publication number
- MX359854B MX359854B MX2014008728A MX2014008728A MX359854B MX 359854 B MX359854 B MX 359854B MX 2014008728 A MX2014008728 A MX 2014008728A MX 2014008728 A MX2014008728 A MX 2014008728A MX 359854 B MX359854 B MX 359854B
- Authority
- MX
- Mexico
- Prior art keywords
- cxcr3
- antibodies
- cxcr3 antibodies
- diagnose
- onset
- Prior art date
Links
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 abstract 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588936P | 2012-01-20 | 2012-01-20 | |
| PCT/US2013/022280 WO2013109974A2 (en) | 2012-01-20 | 2013-01-18 | Anti-cxcr3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014008728A MX2014008728A (es) | 2015-07-06 |
| MX359854B true MX359854B (es) | 2018-10-12 |
Family
ID=47633576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014008728A MX359854B (es) | 2012-01-20 | 2013-01-18 | Anticuerpos anti-cxcr3. |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8865870B2 (OSRAM) |
| EP (1) | EP2804878B1 (OSRAM) |
| JP (3) | JP6352812B6 (OSRAM) |
| KR (2) | KR102073034B1 (OSRAM) |
| CN (1) | CN104507967B (OSRAM) |
| AR (1) | AR090056A1 (OSRAM) |
| AU (1) | AU2013209492B2 (OSRAM) |
| BR (1) | BR112014017814A8 (OSRAM) |
| CA (1) | CA2862222A1 (OSRAM) |
| CY (1) | CY1121335T1 (OSRAM) |
| DK (1) | DK2804878T3 (OSRAM) |
| ES (1) | ES2698606T3 (OSRAM) |
| HR (1) | HRP20181874T1 (OSRAM) |
| HU (1) | HUE041900T2 (OSRAM) |
| IL (2) | IL233694A0 (OSRAM) |
| LT (1) | LT2804878T (OSRAM) |
| MX (1) | MX359854B (OSRAM) |
| PL (1) | PL2804878T3 (OSRAM) |
| PT (1) | PT2804878T (OSRAM) |
| RS (1) | RS58141B1 (OSRAM) |
| RU (1) | RU2663141C2 (OSRAM) |
| SG (2) | SG10201700735PA (OSRAM) |
| SI (1) | SI2804878T1 (OSRAM) |
| TW (1) | TWI596112B (OSRAM) |
| UY (1) | UY34582A (OSRAM) |
| WO (1) | WO2013109974A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| MA40526A (fr) | 2014-08-22 | 2017-06-28 | Sorrento Therapeutics Inc | Protéines de fixation antigénique fixant le cxcr3 |
| CN108431041B (zh) | 2015-10-29 | 2022-08-16 | 艾利妥 | 抗siglec-9抗体及其使用方法 |
| EP3464349A4 (en) * | 2016-05-23 | 2020-08-26 | New York University | COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS |
| EP3559036A1 (en) * | 2016-12-22 | 2019-10-30 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
| KR20190095943A (ko) * | 2016-12-22 | 2019-08-16 | 사노피 | 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법 |
| TW201840585A (zh) | 2016-12-22 | 2018-11-16 | 法商賽諾菲公司 | 用於白斑病的治療的抗人cxcr3抗體 |
| JP7384811B2 (ja) * | 2018-02-16 | 2023-11-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 白斑を処置するための方法及び組成物 |
| KR102074798B1 (ko) * | 2018-06-15 | 2020-02-07 | 코아스템(주) | 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도 |
| BR112021009325A2 (pt) * | 2018-11-14 | 2021-09-14 | Arch Oncology, Inc. | Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica |
| HRP20231031T1 (hr) | 2020-02-26 | 2023-12-22 | Vir Biotechnology, Inc. | Protutijela protiv sars-cov-2 |
| BR112022021992A2 (pt) * | 2020-04-30 | 2023-01-03 | Arch Oncology Inc | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| KR20230154020A (ko) * | 2021-03-02 | 2023-11-07 | 노바록 바이오테라퓨틱스 리미티드 | 클라우딘-6에 대한 항체 및 이의 용도 |
| AU2022326544A1 (en) * | 2021-08-09 | 2024-02-29 | Merck Patent Gmbh | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| EP4583878A1 (en) | 2022-09-09 | 2025-07-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU4434585A (en) | 1985-03-30 | 1986-10-23 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| JP2826272B2 (ja) | 1993-10-26 | 1998-11-18 | タイガースポリマー株式会社 | 中空樹脂成形品の製造装置及び製造方法 |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| DE69737656T2 (de) * | 1996-09-10 | 2008-01-03 | Theodor Kocher Institut | Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2001072334A2 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Methods for treating disease with antibodies to cxcr3 |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| RU2006102570A (ru) * | 2003-06-30 | 2007-08-20 | Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) | Антитела и их применение |
| EP1631315B1 (en) | 2003-09-24 | 2014-07-30 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| JP4695133B2 (ja) * | 2004-03-23 | 2011-06-08 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
| CA2578613A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| JP2009538273A (ja) | 2006-04-14 | 2009-11-05 | トルビオン ファーマシューティカルズ， インコーポレイテッド | 改造されたＦＣエフェクター機能を持つ、免疫グロブリン・ヒンジ領域とＦｃ領域とを備える結合タンパク質 |
| JP5371780B2 (ja) * | 2007-02-01 | 2013-12-18 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Ｃｘｃｒ３に対するヒト化抗体 |
| HUE037489T2 (hu) | 2007-08-29 | 2018-08-28 | Sanofi Sa | Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk |
| US20100130476A1 (en) | 2008-11-12 | 2010-05-27 | The Scripps Research Institute | Compounds that induce pancreatic beta-cell expansion |
| WO2010103517A1 (en) * | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| CN110655573B (zh) * | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
-
2013
- 2013-01-18 PL PL13702548T patent/PL2804878T3/pl unknown
- 2013-01-18 SI SI201331249T patent/SI2804878T1/sl unknown
- 2013-01-18 AU AU2013209492A patent/AU2013209492B2/en not_active Ceased
- 2013-01-18 JP JP2014553482A patent/JP6352812B6/ja not_active Expired - Fee Related
- 2013-01-18 HU HUE13702548A patent/HUE041900T2/hu unknown
- 2013-01-18 BR BR112014017814A patent/BR112014017814A8/pt not_active Application Discontinuation
- 2013-01-18 EP EP13702548.2A patent/EP2804878B1/en active Active
- 2013-01-18 ES ES13702548T patent/ES2698606T3/es active Active
- 2013-01-18 RS RS20181422A patent/RS58141B1/sr unknown
- 2013-01-18 LT LTEP13702548.2T patent/LT2804878T/lt unknown
- 2013-01-18 DK DK13702548.2T patent/DK2804878T3/en active
- 2013-01-18 RU RU2014134043A patent/RU2663141C2/ru active
- 2013-01-18 MX MX2014008728A patent/MX359854B/es active IP Right Grant
- 2013-01-18 KR KR1020147023225A patent/KR102073034B1/ko not_active Expired - Fee Related
- 2013-01-18 SG SG10201700735PA patent/SG10201700735PA/en unknown
- 2013-01-18 CA CA2862222A patent/CA2862222A1/en not_active Abandoned
- 2013-01-18 PT PT13702548T patent/PT2804878T/pt unknown
- 2013-01-18 US US13/745,377 patent/US8865870B2/en not_active Expired - Fee Related
- 2013-01-18 SG SG11201406762QA patent/SG11201406762QA/en unknown
- 2013-01-18 KR KR1020207002561A patent/KR20200014441A/ko not_active Ceased
- 2013-01-18 CN CN201380015401.8A patent/CN104507967B/zh not_active Expired - Fee Related
- 2013-01-18 WO PCT/US2013/022280 patent/WO2013109974A2/en not_active Ceased
- 2013-01-18 HR HRP20181874TT patent/HRP20181874T1/hr unknown
- 2013-01-21 TW TW102102282A patent/TWI596112B/zh not_active IP Right Cessation
- 2013-01-21 UY UY0001034582A patent/UY34582A/es not_active Application Discontinuation
- 2013-01-21 AR ARP130100184A patent/AR090056A1/es unknown
-
2014
- 2014-07-17 IL IL233694A patent/IL233694A0/en unknown
- 2014-09-08 US US14/480,052 patent/US9765144B2/en not_active Expired - Fee Related
-
2017
- 2017-08-04 US US15/669,556 patent/US20180086838A1/en not_active Abandoned
-
2018
- 2018-05-07 JP JP2018089004A patent/JP6646100B2/ja not_active Expired - Fee Related
- 2018-09-14 US US16/132,333 patent/US20190119391A1/en not_active Abandoned
- 2018-11-22 CY CY20181101236T patent/CY1121335T1/el unknown
-
2019
- 2019-12-24 IL IL271697A patent/IL271697A/en unknown
-
2020
- 2020-01-08 JP JP2020001152A patent/JP2020072715A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX359854B (es) | Anticuerpos anti-cxcr3. | |
| WO2011113019A3 (en) | Ctla4 proteins and their uses | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| PH12013501636A1 (en) | Treatment of osteoarthritis and pain | |
| PH12013501490A1 (en) | Methods for diagnosing and treating eye-length related disorders | |
| MX2022004300A (es) | Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas. | |
| PH12013502568B1 (en) | Anti-psgl-1 antibodies and uses thereof | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| WO2010025321A3 (en) | Method for treating multiple sclerosis patients with anti-il2r antibodies | |
| WO2013022740A3 (en) | Gpr35 ligands and the uses thereof | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| MX2013013685A (es) | Metodo para tratar articulos con dioxido de carbono. | |
| IN2015KN00492A (OSRAM) | ||
| MX2014009750A (es) | Composiciones antifungicas para el tratamiento de piel y uñas. | |
| UA103197C2 (uk) | Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами | |
| EP2597949A4 (en) | SUBMIKROMETERZUSAMMENSETZUNGEN | |
| WO2012138653A3 (en) | Treatment regimens | |
| WO2012136351A8 (en) | Tapentadol for treating pain associated with trigeminal neuralgia | |
| WO2013090319A3 (en) | Treatment of type i and type ii diabetes | |
| HK1199842A1 (en) | Anti-siglec-15 antibodies and uses thereof | |
| GB201006938D0 (en) | Granulysin and derived peptides:use as novel anthelmintic molecules | |
| TN2010000463A1 (en) | Compositions and methods for preparing and using same | |
| HK1221666A1 (zh) | 氨基吡啶用於治疗与某些中风类型相关的视觉障碍的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |